Journal article
Low-Dose Estramustine Phosphate and Concomitant Low-Dose Acetylsalicylic Acid in Heavily Pretreated Patients With Advanced Castration-Resistant Prostate Cancer
Clinical genitourinary cancer, Vol.13(5), pp.441-446
10/01/2015
DOI: 10.1016/j.clgc.2015.03.004
PMID: 25920994
Abstract
Several new drugs with different mechanisms of action have been recently developed for the treatment of castration-resistant prostate cancer (CRPC). However, few data are available for the efficacy of other treatment options after disease progression occurs after therapy with new agents. Estramustine phosphate (EMP) previously demonstrated activity and manageable toxicity in advanced CRPC, with thromboembolic events sometimes reported with its use. The current phase 2 study suggested that low-dose EMP with concomitant low-dose acetylsalicylic acid as thromboprophylactic agents may achieve some activity in heavily pretreated advanced CRPC patients.
Background: The aim of this phase 2 study was to evaluate the activity and tolerability of low-dose estramustine phosphate (EMP) with concomitant low-dose acetylsalicylic acid (ASA) as a thromboprophylactic agent in heavily pretreated patients with advanced castration-resistant prostate cancer. Methods: Patients received 420 mg of oral EMP twice daily and oral ASA 100 mg once daily. The primary endpoint was prostate-specific antigen response. All of the patients had been previously treated with docetaxel and abiraterone acetate, and 12 had also received cabazitaxel. Results: Thirty-one patients were enrolled. Prostate-specific antigen response was observed in 9 patients (29.0%; 95% confidence interval [CI], 14-48). Median progression-free survival was 3.6 months (95% CI, 2.2-5.6), and median overall survival was 7.6 months (95% CI, 6.9-9.7). Treatment was generally well tolerated, and no grade 3/4 toxicity was observed. Ten patients (32.2%) had grade 2 nausea and vomiting. No cardiovascular event and no major bleeding occurred. No venous thromboembolism event was observed. Conclusion: Low-dose EMP with concomitant low-dose ASA seems to be a safe treatment option with some activity for patients with advanced castration-resistant prostate cancer who have been heavily pretreated. (C) 2015 Elsevier Inc. All rights reserved.
Details
- Title: Subtitle
- Low-Dose Estramustine Phosphate and Concomitant Low-Dose Acetylsalicylic Acid in Heavily Pretreated Patients With Advanced Castration-Resistant Prostate Cancer
- Creators
- Roberto Petrioli - University of SienaGiandomenico Roviello - University of SienaAnna I. Fiaschi - University of SienaLetizia Laera - University of SienaVincenzo Bianco - Policlinico Umberto IRoberto Ponchietti - University of SienaGabriele Barbanti - University of SienaEdoardo Francini - Policlinico Umberto I
- Resource Type
- Journal article
- Publication Details
- Clinical genitourinary cancer, Vol.13(5), pp.441-446
- DOI
- 10.1016/j.clgc.2015.03.004
- PMID
- 25920994
- ISSN
- 1558-7673
- eISSN
- 1938-0682
- Publisher
- Cig Media Group, Lp
- Number of pages
- 6
- Language
- English
- Date published
- 10/01/2015
- Academic Unit
- Internal Medicine
- Record Identifier
- 9985221147802771
Metrics
1 Record Views